-
FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREEDismiss Notice
-
Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.Dismiss Notice
CEO search
Discussion in 'American Pathology Partners' started by anonymous, Mar 29, 2018 at 7:12 PM.